Clinical trial
Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma - a Phase 1 Trial
NCT04163107 is registered in ClinicalTrials.gov with Norwegian University of Science and Technology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma - a Phase 1 Trial
- Lead sponsor
- Norwegian University of Science and Technology
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 7, 2020
- Completion date
- December 28, 2021
- Enrollment
- 19 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.